Particle.news
Download on the App Store
6 ARTICLES
·
3w ago

Wockhardt Liquidates US Generics Units to Fuel Antibiotic and Insulin Innovation

Chapter 7 liquidation of its Delaware subsidiaries clears capital for a planned August NDA filing for Zaynich in support of Wockhardt’s shift toward higher-margin research-led pharmaceuticals.

Image
Image
Image
Image

Overview

  • On July 11, Wockhardt filed for voluntary Chapter 7 liquidation of Morton Grove Pharmaceuticals Inc and Wockhardt USA LLC to exit its loss-making US generics business.
  • The US generics arm posted nearly $8 million in losses in FY25, eroding profitability and prompting the strategic withdrawal.
  • Freed resources will back a New Drug Application for Zaynich, Wockhardt’s antibiotic candidate targeting multi-drug resistant infections, slated for FDA submission in August 2025.
  • The company is accelerating its insulin biologics program, leveraging advanced technologies to address critical unmet needs in diabetes care.
  • Wockhardt reaffirmed its commitment to profitable operations in India, the United Kingdom, Ireland and Europe as it reallocates focus and capital toward innovation-driven portfolios.